Excelsior Biopharma Inc. (TPEX:6496)

Market Cap	1.25B
Revenue (ttm)	881.71M
Net Income (ttm)	-105.89M
Shares Out	46.75M
EPS (ttm)	-2.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,753
Average Volume	17,345
Open	25.80
Previous Close	26.45
Day's Range	25.65 - 26.75
52-Week Range	21.55 - 35.40
Beta	-0.03
RSI	64.90
Earnings Date	Aug 14, 2025

About Verve Therapeutics

Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers prescription drugs, over-the-counter drugs, medical devices, healthcare food products, medical supplies, and other products. The company provides its products for the therapeutic areas, such as pediatrics, gastroenterology, neurology, cardiology, dermatology, medical toxicology, dentistry, obstetrics, oncology, hematology, and otorhinolaryngology, as well as infectious diseases. It also offers test kits under the Actim name to de...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1988
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6496

Financial Performance

In 2024, Excelsior Biopharma's revenue was 861.91 million, an increase of 11.71% compared to the previous year's 771.56 million. Losses were -98.71 million, 8.45% more than in 2023.